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Abstract
Background: A reliable blood-based assay is required to properly diagnose and monitor Alzheimer’s disease (AD).
Many attempts have been made to develop such a diagnostic tool by measuring amyloid-β oligomers (AβOs) in
the blood, but none have been successful in terms of method reliability. We present a multimer detection system
(MDS), initially developed for the detection of prion oligomers in the blood, to detect AβOs.
Methods: To characterize Aβ in the blood, plasma was spiked with synthetic amyloid-β (Aβ) and incubated over
time. Then, the MDS was used to monitor the dynamic changes of AβO levels in the plasma.
Results: Increasing concentrations of AβOs were observed in the plasma of patients with AD but not in the plasma
of normal control subjects. The plasma from patients with AD (n = 27) was differentiated from that of the age-
matched normal control subjects (n = 144) with a sensitivity of 83.3% and a specificity of 90.0%.
Conclusions: Synthetic Aβ spiked into the blood plasma of patients with AD, but that of not elderly normal control
subjects, induced dynamic changes in the formation of AβOs over time. AβOs were detected by the MDS, which is
a useful blood-based assay with high sensitivity and specificity for AD diagnosis.
Keywords: Multimer detection system, Alzheimer’s disease, Amyloid-β, Oligomers, Blood biomarker, Synthetic
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Background
Amyloid-β (Aβ) is a major factor in the pathogenesis of
Alzheimer’s disease (AD) [1–3]. Aβ may be involved in the
cognitive impairment of memory that leads to AD, particu-
larly in the form of aggregated 42-amino acid isoform of
the Aβ peptide (Aβ42), which is a major neurotoxic species
among Aβ isomers, including Aβ40, Aβ42, and other trun-
cated forms of Aβ [4–10]. Since the initial identification of
these Aβ isomers in bodily fluids, the measurement of Aβ
levels in the blood and cerebrospinal fluid (CSF) has been a
research priority [11, 12]. Three biomarkers in CSF, specif-
ically Aβ42, total tau, and hyperphosphorylated tau, are
widely accepted as AD determinants on the basis of their
close correlations with AD pathology [13, 14]. Diagnostic
imaging using positron emission tomography (PET) is the
preferred method of investigating pathological and
functional changes in the brain of patient with AD. 11C- or
18F-labeled Pittsburgh compound B-positron emission tom-
ography (PiB-PET), which involves binding to amyloid de-
positions, is particularly beneficial for understanding the
underlying processes of AD. Therefore, this type of imaging
is used both in research and in the clinic to differentiate pa-
tients with AD from control subjects and individuals with
other types of dementia [15–17].
Several noninvasive diagnostics for AD, based on diverse
biomarkers in the saliva, urine, and blood, have been re-
ported and are still in the research phase of development
[18–21]. Mapstone et al. [22] identified a panel of ten plasma
phospholipids as potential diagnostic biomarkers of AD,
which included lysophosphatidylcholine, phosphatidylcholine
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metabolites, and acylcarnitine metabolites. This plasma lipid
panel predicted AD conversion, suggesting 90% sensitivity
and 85% specificity in differentiating an at-risk group from
the cognitively intact group. Despite encouraging results,
low positive predictive values limited the clinical usefulness
of this panel as a screening tool in subjects aged 70–80 years
or younger. In another study, significant differences in sol-
uble CD40 (sCD40) and sCD40 ligand (sCD40L) levels in
plasma were observed between AD cases and control sub-
jects. sCD40 was approximately three times higher in pa-
tients with AD than in control subjects with sensitivity and
specificity of 68% and 84%, respectively. Similarly, concentra-
tions of sCD40L were 2.27 times higher in AD cases than in
control subjects with sensitivity and specificity of 51% and
76%, respectively [23]. A biomarker panel of cortisol, pancre-
atic polypeptide, insulin-like growth factor binding protein 2,
β2-microglobulin, vascular cell adhesion molecule 1, carci-
noembryonic antigen, matrix metalloproteinase 2, CD40,
macrophage inflammatory protein 1α, superoxide dismutase,
and homocysteine was shown to significantly increase in
plasma from patients with AD. In addition, apolipoprotein E
(ApoE), epidermal growth factor receptor, hemoglobin, cal-
cium, zinc, interleukin (IL)-17, and albumin were revealed to
be decreased in patients with AD. Cross-validated accuracy
measures from the Australian Imaging, Biomarker & Life-
style Flagship Study of Ageing (AIBL) cohort reached a
mean (SD) of 85% (3.0%) for sensitivity and specificity and
93% (3.0) for the AUROC. A second validation using the
Alzheimer’s Disease Neuroimaging Initiative cohort showed
accuracy measures of 80% (3.0%) for sensitivity and specifi-
city and 85% (3.0) for the AUROC [24]. Eighteen signaling
blood proteins in hematopoiesis, immune responses, apop-
tosis, and neuronal supports were suggested to differentiate
patients with AD from control subjects with close to 90% ac-
curacy and also to identify patients who would convert from
mild cognitive impairment to AD 2–6 years later [25].
Among these, methods employing blood-based bio-
markers have been focused on the detection of amyloid-β
oligomers (AβOs) and other surrogate biomarkers of AD
[26–31]. Experimental cross-sectional analyses undertaken
to detect AβOs in the plasma have demonstrated limited
and inconclusive results [26–28]. Other blood-based sur-
rogate biomarkers, including ApoE, inflammatory markers
(IL-8, IL-1a), Aβ autoantibodies, total serum cholesterol,
and microRNAs (specifically miR-9, miR-29a, miR-29b,
miR101, miR-125b, miR-132, miR-134, and miR-181c),
have also demonstrated variability as disease correlates
[29–31]. Although there have been difficulties in develop-
ing methods for AD diagnosis using blood-based bio-
markers, a reliable and reproducible blood-based assay is
still needed for clinical use [32].
A multimer detection system (MDS) was originally devel-
oped to detect prion oligomers in the blood of scrapie-
infected animals. MDS is a sandwich enzyme-linked
immunosorbent assay (ELISA) that preferentially detects
oligomers over monomers by creating steric hindrance be-
tween capturing and detection antibodies that are specific
to a unique/overlapping epitope [33].
In the present study, MDS for AD was developed to de-
tect AβOs using two different antibodies against the N-
terminus of Aβ. Initially, MDS was unable to differentiate
AβOs in the blood of patients with AD from those of nor-
mal control subjects. Synthetic Aβ was then spiked into
the plasma of patients with AD and control subjects.
Using MDS, the dynamic changes of AβO formation were
detected in the spiked plasma of patients with AD but not
in the spiked plasma of control subjects. Therefore, in this
study, we evaluated the dynamic changes of AβO levels in
the plasma of patients with AD compared with those of
normal age-matched control subjects.
Methods
Clinical data
This study was approved by the institutional review board of
Seoul National University Bundang and Chung-Ang
University Hospital [B-0905-075-003, B-1202-145-003,
C2012048(743), C2013142(1102)]. Pooled plasma samples
were collected from 11 patients with AD and 9 elderly nor-
mal control subjects, and individual plasma samples of 24
patients with AD and 29 healthy elderly normal control sub-
jects were collected from either Seoul National University
Bundang Hospital or Chung-Ang University Hospital
(Table 1). Written informed consent was obtained from all
patients who participated in this study or from their care-
givers. AD cases were each diagnosed with a probable AD
amnestic type on the basis of clinical criteria of the National
Institute on Aging-Alzheimer’s Association workgroups
within a clinical setting with clinical data and follow-up
longer than 6 month before inclusion into PiB-PET or CSF
studies. Hence, the recruited patients were clinically well-
characterized patients with AD, and only they were included
in the study. They were diagnosed with AD after initial
workup and had not shown any possibility of other neurode-
generative disorders except AD or secondary dementia dis-
orders on the basis of more than 6 months of follow-up.
The Mini Mental State Examination, identification of the
ApoE phenotype, PET imaging with PiB and 18F-fluoro-
deoxyglucose, and CSF analysis were performed. The char-
acteristics of all participants are described in Table 1. Fifty-
one additional plasma samples from elderly normal control
subjects were included to avoid false positivity (Table 2).
Sample preparation
Blood samples were collected in heparin-containing tubes
and centrifuged at 850 × g for 30 minutes. The plasma
(supernatant) was divided into aliquots and stored at −80 °C
until analysis. Plasma samples of patients with AD (n = 11)
and elderly normal control subjects (n = 9) were separately
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pooled for initial method optimization, whereas the
remaining samples were assessed individually.
Preparation of synthetic Aβ42
Lyophilized AggreSure β-Amyloid (1–42) peptide
(AnaSpec, Fremont, CA, USA) and double-mutant F19S/
L34P Aβ42 (mutAβ42; AnyGen Co., Ltd., Gwangju, South
Korea) were each dissolved in 50 mM Tris/150 mM NaCl
(pH 7.2) at a concentration of 1 mg/ml and then sonicated
for 5 minutes to obtain a homogeneous solution. The pep-
tide solution was further diluted with phosphate-buffered
saline containing Tween 20 (PBST; Sigma-Aldrich, St.
Louis, MO, USA) to a desired concentration of 10 μg/ml.
Solutions of diluted peptides were divided into aliquots
and kept at −80 °C until further use.
Thioflavin T assay
Aβ aggregation was monitored using a thioflavin T (ThT)
assay kit following the suggested protocol of the manufac-
turer (AnaSpec). Ninety microliters of test sample and 10
μl of 2 mM ThT solution were added to each well of a 96-
well plate (Thermo Fisher Scientific, Waltham, MA, USA),
and the plates were incubated for different lengths of time.
Then, changes in ThT fluorescence intensity were detected
by measuring excitation and emission wavelengths of 440
nm and 484 nm, respectively, using a multispectrophot-
ometer (Victor 3TM; PerkinElmer, Waltham, MA, USA)
with 15 seconds of shaking before reading and analysis.
TEM
AβO, protofibrils, and fibrils were characterized by TEM
at various incubation times (0, 1, 3, 6, 24, and 48 h). Five
microliters of each sample was applied to carbon-coated
TEM grids that had previously been glow-discharged for 3
minutes in the air and immediately negatively stained (~5
seconds) with 2% uranyl acetate. Excess solution was re-
moved with blotting paper. Image acquisition was carried
out using a Philips CM10 transmission electron micro-
scope (Philips Research, Eindhoven, The Netherlands)
with an accelerating voltage of 80 kV.
Sodium dodecyl sulfate-PAGE and immunoblotting
The aggregation state of Aβ was also analyzed by sodium
dodecyl sulfate-PAGE followed by Western blotting.
Synthetic peptide samples were electrophoresed on a 10–
20% Tris-Tricine precast gel (Bio-Rad Laboratories,
Hercules, CA, USA) and visualized by Coomassie blue
staining (Bio-Rad Laboratories). After electrophoresis, the
proteins were transferred to a polyvinylidene fluoride
membrane (Bio-Rad Laboratories), which was blocked
with 2% Block Ace (Bio-Rad Laboratories) in Tris-
buffered saline containing Tween 20 (TBST; Sigma-
Aldrich) for 1 h at room temperature (RT) under condi-
tions to reduce nonspecific binding. The membrane was
incubated for 1 h at RT with a horseradish peroxidase
(HRP)-conjugated FF51 antibody (FF51-HRP antibody;
PeopleBio Inc., Seoul, South Korea) diluted in 0.4% Block
Ace in TBST. Proteins bound to the antibody were
visualized with 3,3′,5,5′-tetramethylbenzadine reagent
(Sigma-Aldrich).
Table 1 Characterization of patients with Alzheimer’s disease
and healthy normal control subjects
AD Healthy normal
control subjects
Total sample number 24 29
Sex
Female 13 (54.2%) 16 (55.2%)
Male 11 (45.8%) 13 (44.8%)
Age, years (SD) 67.6 (±7.4) 62.4 (±5.7)
Education, years (SD) 13.1 (±3.9) 13.2 (±3.5)
CDR-SOB, mean 6.35 0.03
MMSE score, mean 17.7 29.03
ApoE ε4, % 47.8 21.7
Note test 1 0
Number of plasma samples 24 29
CSF markers 23 28
Aβ42, pg/ml, mean (SD) 258.6 (±70.8) 464.8 (±114.4)
p-Tau, pg/ml, mean (SD) 58.6 (±18.6) 28.0 (±14.3)
t-Tau, pg/ml, mean (SD) 132.1 (±61.8) 62.1 (±20.3)
PiB-PET number 23 28
Mean SUVR 1.57 1.14
FDG-PET number 18 28
Mean SUVR 0.9 1.06
Abbreviations: Aβ42 Amyloid-β 1–42 peptide, AD Alzheimer’s disease, ApoE
Apolipoprotein E, CDR-SOB Clinical Dementia Rating Sum of Boxes, CSF
Cerebrospinal fluid, FDG 18F-fluorodeoxyglucose, MMSE Mini Mental State
Examination, PET Positron emission tomography, PiB 11C-Pittsburgh compound
B, p-Tau Phosphorylated tau protein, SUVR Standardized uptake value ratio,
t-Tau Total tau protein
Table 2 Supplementary information on healthy normal control
subjects
Healthy normal control subjects




Age, years (SD) 62.25 (±7.89)
Education, years (SD) 10.35 (±3.29)
CDR-SOB 0.03
MMSE score 28.27
CDR-SOB Clinical Dementia Rating Sum of Boxes, MMSE Mini Mental
State Examination
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MDS for Alzheimer’s disease
A modified MDS was used to measure AβOs. With this
method, epitope-overlapping antibodies specific for the N-
terminus of Aβ were used to capture and detect the Aβ
antigen in its multimeric or oligomeric form. Because
MDS was initially developed to detect prion oligomers
using prion antibodies, over 100 sets of antibodies against
Aβ were screened (data not shown). In addition, in-house
Aβ antibodies were developed. The mouse monoclonal
antibody 6E10 (BioLegend, San Diego, CA, USA) and an
in-house FF51-HRP antibody were chosen to detect AβOs
in our modified MDS, owing to their sensitivity and speci-
ficity. The epitopes for these antibodies overlap at the N-
terminus of Aβ. The FF51 antibody specifically recognizes
amino acid residues 1–4 of Aβ.
To use MDS, the 6E10 antibody was coated overnight
at 4 °C in the wells of a 96-well black plate (Thermo
Fisher Scientific) at a dilution of 3 μg/ml in carbonate-
bicarbonate buffer (Sigma-Aldrich). The plates were
blocked for 2 h with 0.4% Block Ace (100 μl) at RT.
After washing three times with PBS (Sigma-Aldrich), the
plate was stored at 4 °C until use. Prior to the assay, ali-
quots of plasma samples were thawed at 37 °C for 15
minutes. Ten microliters of plasma, 4.04 μl of HBR-1, a
HAMA blocker (Scantibodies Laboratory, Santee, CA,
USA), and PBST were mixed. We spiked the synthetic
Aβ42 into plasma mixture and incubated it at 37 °C for
the indicated durations.
The plasma sample mixture and serially diluted stan-
dards were added to each well of the plate in a total vol-
ume of 100 μl. The plates were incubated at RT for 1 h.
After washing three times with TBST, the FF51-HRP
antibody in TBST containing 0.4% Block Ace was added
to the wells, and the plate was incubated for 1 h at RT.
To increase the sensitivity of detection, 100 μl/well of
enhanced chemiluminescence substrate solution (Rock-
land Immunochemicals Inc., Limerick, PA, USA) was
used, and the luminescent signal was detected and quan-
tified using a Victor 3TM multispectrophotometer.
Measurement of Aβ monomers (Aβ40 and Aβ42)
Sandwich ELISAs were performed to measure Aβ40 and
Aβ42 monomer levels. Aβ40 monomers were captured
with the 11A50 antibody (specific for the C-terminus of
Aβ40) and detected with the 1E11 antibody conjugated
to biotin. Aβ42 monomers were captured with the 12F4
antibody (specific for the C-terminus of Aβ42) and de-
tected with the 1E11 antibody conjugated to biotin.
Statistics
Statistical evaluations were performed using the Mann-
Whitney U test followed by the calculation of two-tailed
p values to determine the significance between groups.
Results
Measuring dynamic changes of AβO levels with MDS
Aβ42 was characterized by gel electrophoresis, Western
blotting, and TEM before it was spiked into plasma
samples (Fig. 1). On the basis of Coomassie blue staining of
dissolved Aβ42, a smear band containing monomers and
low-molecular-weight oligomers ranging between 4 and 18
kDa in size was detected, as shown in Fig. 1a. A double-
mutant, Aβ42 (F19S/L34P; mutAβ42), was used as a mono-
meric Aβ control because this mutant has significantly re-
duced aggregation potential as shown by Western blotting,
which yielded a specific band with an approximate molecu-
lar weight of 4–5 kDa. The specificities of the wild-type and
mutant monomer bands were verified by MDS, as shown
in Fig. 1b. MDS was capable of detecting AβOs composed
of Aβ42 in a concentration-dependent manner employing
half serial dilutions from 100 ng to 3.13 ng, whereas no sig-
nal was detected when using mutAβ42. Thus, MDS specific-
ally recognizes AβOs but not Aβmonomers.
As shown in Fig. 1c, changes in Aβ42 oligomer levels over
an incubation period of 144 h were monitored using an
MDS and the ThT assay. The MDS detected a continual in-
crease in Aβ42 oligomer levels from 0 to 24 h after the start
of incubation, followed by a decline until 120 h, at which
point the levels remained relatively stable. Conversely, the
ThT assay showed an increase in Aβ42 oligomer levels from
0 to 48 h, at which point changes in β-sheet formation were
observed. TEM (Fig. 1d) revealed a wide range (1–5 nm) of
AβO diameters, with few protofibrils observed. These find-
ings support the MDS results obtained at the start of incu-
bation (0 h) in terms of the formation of AβOs. Within 1 h
after the start of incubation, the Aβ42 monomers readily
formed large, spherical AβOs ranging from 10 to 15 nm in
size, and numerous protofibrils were observed (lengths of
50–80 nm). A TEM image at 3 h revealed the elongation of
AβOs to form protofibrils, and significant amounts of large
AβOs and protofibrils were observed at 6 h by TEM. A
substantial decline in the MDS signal was observed during
the time interval of 24–48 h after the start of incubation.
TEM revealed the predominance of protofibrils and fibrils
(over 120 nm in length) at 24 h, whereas AβOs were rarely
observed, and the continuous maturation of protofibrils re-
sulted in an increase in Aβ42 fibrils at 48 h. On the basis of
these findings, the MDS sensitively and specifically detects
oligomeric and protofibril forms of Aβ, permitting their
quantification, whereas the ThT assay is not sensitive and
was incapable of detecting increases in Aβ fibril levels,
including diverse types of amyloid fibrils [34].
Plasma is cleared of Aβ through several intricate mecha-
nisms of aggregation or sequestration [35–38]. Therefore,
pooled samples of plasma from patients with AD or from
normal control subjects were spiked with different concen-
trations of Aβ42 to compare differences in Aβ42 recovery
(Fig. 2a and b). AβO levels were reduced in accordance
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with the Aβ42 concentrations used for spiking when com-
pared with AβO levels in a solution spiked with buffer.
Lower concentrations of spiked Aβ42 yielded smaller differ-
ences in the formation of AβOs in the pooled plasma of pa-
tients with AD compared with that of control subjects. For
subsequent experiments, 10 ng/ml Aβ42 was chosen for
spiking into plasma because this concentration yielded the
smallest measurable difference in the recovery rate of Aβ
when comparing plasma from patients with AD with that
of normal control subjects. Eleven plasma samples from
patients with AD and nine from elderly normal control
subjects were separately pooled for each group. Pooled
Fig. 1 Detection of synthetic amyloid-β 1–42 peptide (Aβ42). a Freshly dissolved synthetic Aβ42 and double-mutant Aβ42 (mutAβ42) were visualized on
the 4–12% aspartate PAGE gel by Coomassie blue staining and on the Western blot by FF51-horseradish peroxidase (HRP) antibody. b Standard curve
for multimer detection system (MDS). Synthetic peptides were serially diluted and measured by 6E10/FF51-HRP MDS assay. Change of Aβ42 over
different times (c and d). Aβ42 was incubated at 37 °C at the indicated time points. To measure amyloid-β oligomer (AβO), an MDS assay was used (c),
and fibrillization of Aβ42 over time was measured by thioflavin T (ThT) binding assay (d). TEM images over time by Aβ42 in buffer vehicle are shown.
Data are mean ± SD. RLU Relative luminescence units, RFU Relative fluorescence units
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samples were incubated at 37 °C after spiking with Aβ42 (10
ng/ml), and the presence of oligomers was measured using
MDS at various time points after the start of incubation. As
shown in Fig. 2b, both groups exhibited a gradual decline
in oligomer levels over 48 h of incubation; the two groups
demonstrated similar levels over this time period. After 48
h of incubation, distinct dynamic changes were observed
between the plasma from patients with AD and that of eld-
erly normal control subjects. Larger increases in AβO levels
were observed in the plasma from patients with AD after
48 h of incubation, and levels continually increased
throughout the rest of the incubation period. In contrast,
AβO levels in the plasma from elderly normal control sub-
jects gradually decreased until 72 h after the start of incuba-
tion, then rebounded with a considerable increase until 144
h. The largest differences in AβO levels between plasma
from patients with AD and plasma from elderly normal
control subjects were observed after 144 h of incubation
following spiking with Aβ. Changes in Aβ40 and Aβ42 levels
after spiking with Aβ42 were also measured by performing
11A50/1E11-biotin ELISA and 12F4/1E11-biotin ELISA.
Aβ40 and Aβ42 levels remained relatively unchanged over
the incubation period (Fig. 2c and d), whereas significant
increases in the oligomer forms, as measured by MDS,
were observed in the plasma from patients with AD after
48 h of incubation but not in plasma from elderly normal
control subjects. Additional experiments were then per-
formed to confirm whether the differential changes in the
Aβ forms were discernible in individual plasma samples.
Plasma samples corresponding to individuals included in
the pooled groups (patients with AD and elderly normal
control subjects) were spiked with Aβ42. Then, MDS was
used to monitor changes in AβO levels during incubation
from 0 to 144 h (Fig. 3a and b). Each sample was also tested
in the absence of synthetic Aβ for comparison. As shown
in Fig. 3b1, AβO levels in plasma samples from patients
with AD and elderly normal control subjects overlapped
without a significant difference (p = 0.6761) at 0 h, regard-
less of spiking. In contrast, after 144 h of incubation, dis-
tinct oligomer levels were detected in Aβ42-spiked samples
from the AD and control groups (p < 0.01) on the basis of
MDS measurements (Fig. 3b2). Plasma samples from the
AD group also demonstrated higher AβO levels than nor-
mal control plasma, although this difference was significant
Fig. 2 Changes of amyloid-β oligomers (AβOs) and amyloid-β (Aβ) monomers in pooled plasma of patients with Alzheimer’s disease (AD) and
healthy normal control subjects. a After being spiked with different concentrations of Aβ42 in buffer vehicle, pooled AD plasma, and pooled
healthy normal control plasma, oligomers were measured using a multimer detection system (MDS) at 0 h. b Pooled plasma samples
were incubated at 37 °C after being spiked with 10 ng/ml Aβ42. Changes of Aβ42 levels at various time points were measured by MDS.
Levels of Aβ40 (c) and Aβ42 (d) after being spiked with 10 ng/ml Aβ42 in pooled human plasma. Pooled plasma samples were incubated
at 37 °C after 10 ng/ml Aβ42 were spiked. Data are mean ± SD. RLU Relative luminescence units. Arrow indicated no change in oligomer
levels after an incubation period of 24 h
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but the p value was < 0.05 (Fig. 3a2). Similar to the results
of the pooled plasma experiment, Aβ dynamics were evi-
dent from 48 to 144 h in individual samples from both
groups. As shown in Fig. 3c, substantial increases in oligo-
mer levels were confirmed in the majority of plasma sam-
ples from patients with AD, whereas samples from normal
control subjects demonstrated no significant increase. No
increases in oligomer levels were observed with synthetic
Aβ42 in buffer solution after an incubation time of 24 h.
Differential dynamic changes in Aβ levels in plasma of
patients with AD versus that of elderly normal control
subjects
To evaluate and verify our findings on a larger scale, 24
plasma samples from clinically well-characterized cases
of AD and 80 from elderly normal control subjects were
examined after spiking with synthetic Aβ (10 ng/ml) and
incubating for 144 h. The dynamic changes of oligomer
formation were measured using MDS, and oligomer
levels were different between the AD and control groups
with a sensitivity of 83.33%, a specificity of 90.00%, an
AUC of 0.8969, and a p value < 0.0001 (Fig. 4).
Discussion
MDS was initially developed to detect prion disease. This
method consists of a sandwich ELISA that exclusively de-
tects oligomeric forms of antigens and relies on two differ-
ent epitope-overlapping antibodies to capture and detect
antigens by creating steric hindrance over a specific epi-
tope [33, 39]. MDS was modified to detect AβOs for AD
Fig. 3 Effect of amyloid-β 1–42 peptide (Aβ42) spiking and incubation in individual subjects (Alzheimer’s disease [AD] and healthy normal control
subjects). Each sample was incubated under the indicated conditions. To measure amyloid-β oligomers, a multimer detection system (MDS) assay
was used. (a1) 0 ng/ml Aβ42 at 0 h, (a2) 0 ng/ml Aβ42 at 144 h, (b1) 10 ng/ml Aβ42 at 0 h, and (b2) 10 ng/ml Aβ42 at 144 h. (c) Dynamic changes
of Aβ42 incubation in individual subjects at 72 h and 144 h. Each sample was incubated for 72 h and 144 h after being spiked with 10 ng/ml
Aβ42 and measured by MDS. *p < 0.05; ** p < 0.01. RLU Relative luminescence units
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diagnosis using two epitope-overlapping Aβ antibodies
specific for the N-terminus amino acids 1–18 of Aβ42.
We monitored the formation of AβO, protofibrils, and fi-
brils from synthetic Aβ42 in PBST buffer employing two
methods: a ThT assay and MDS (Fig. 1). Aβ oligomerization
was closely correlated between these two assays. When the
time-course changes of synthetic Aβ in PBST buffer were
monitored by MDS, ThT assay, and TEM, the MDS de-
tected a continuous increase of Aβ42 oligomer levels from 0
to 24 h from the start of incubation, followed by a decline
until 120 h. Conversely, an increase of fluorescent signal in
the ThT assay was correlated with an increase of Aβ42 fibril
formation, which was confirmed by TEM imaging (Fig. 1c
and d). The MDS signal decreased at that time of fibrilliza-
tion; thus, it would be reasonable to assume that MDS de-
tected specifically oligomeric and protofibril forms of Aβ.
During the early phase of incubation, MDS revealed de-
creasing AβO levels accompanied by the formation of pro-
tofibrils and fibrils, but the levels detected by the ThT assay
were stable. Thus, MDS is able to detect AβOs during the
early stage of Aβ oligomerization. Decreasing AβO levels,
as measured by MDS, in conjunction with the formation of
protofibrils and fibrils is potentially explained by two hy-
potheses. First, MDS has a higher sensitivity for oligomers
than for protofibrils or fibrils. Second, the total number of
oligomers decreases over time. After full oligomerization,
the spiked Aβ converts to protofibrils, resulting in de-
creased MDS signals.
When synthetic Aβ42 is spiked into plasma, the plasma
composition may dictate and interfere with Aβ
oligomerization. Difficulties in detecting spiked synthetic
Aβ42 via routine ELISA may be attributable to the pres-
ence of many different interfering factors in the plasma,
which bind to the spiked synthetic Aβ42 and thus reduce
its detection. These factors include naturally occurring Aβ
autoantibodies, albumin, fibrinogen, immunoglobulin,
ApoJ, ApoE, transthyretin, α2-macroglobulin, serum amyl-
oid P component, plasminogen, and amylin [35–38, 40].
In addition, these molecules in bodily fluids could also
inhibit Aβ fibrillization. Our hypothesis was that the
composition of those components in blood from patients
with AD would be different from that in healthy control
subjects. If the same amount of Aβ were spiked into AD
and control plasma samples, a different phenomenon
would be observed between the two groups.
In this study, when equal amounts of synthetic Aβ42 were
spiked into plasma, MDS signals for AβOs declined from 0
to 48 h in both groups (Fig. 2b), potentially due to AβO
binding to interfering factors. Although binding affinities
and Aβ epitopes likely vary among different binding factors,
high concentrations in the plasma would likely result in the
scavenging of spiked synthetic Aβ42. Binding of these factors
to Aβ may naturally influence the normal functions and se-
questration of Aβ, leading to clearance and reduced
oligomerization potential in elderly normal persons [35, 37].
Forty-eight hours after spiking with Aβ42, AβO levels
measured by MDS began to increase in the plasma from
patients with AD but not in that of normal control subjects
(Fig. 2b). Patients with AD may exhibit different binding
profiles based on their plasma composition in the context
of spiked synthetic Aβ42, which in turn may increase
oligomerization potential and decrease sequestration cap-
acity. Alternatively, the characteristics of endogenous
plasma Aβ may differ between the two groups, permitting
the dynamic changes of Aβ oligomerization to be detected.
It is challenging work to detect crude AβOs in plasma
because the concentrations of Aβ in blood are very low.
Furthermore, the concentrations of AβOs would be a
subset of total Aβ in blood. The size of 4.5 kDa could be
another reason why the MDS failed to measure the
endogenous plasma Aβ from patients with AD. As
shown in Fig. 3, the MDS did not discriminate between
patients with AD and healthy normal control subjects
without incubation conditions. Even though incubation
of plasma samples without spiking external Aβ made
slight differences between AD and normal control
samples, the difference was not significant.
However, even at ultralow concentrations, the formation
of AβO in the blood of patients with AD may be initiated
via incubation with spiked synthetic Aβ42. The first 48 h
of incubation represent a slow nucleation-dependent
oligomerization phase during which ultralow concentra-
tions of AβO nuclei are required to bind to spiked
synthetic Aβ42. The period after 48 h and up to 144 h rep-
resents a rapid-growth phase for the formation of oligo-
mers, protofibrils and fibrils, surpassing the critical
detection limit [34, 41–43]. As previously mentioned, the
Fig. 4 Effect of amyloid-β 1–42 peptide (Aβ42) spiking and incubation
in large scale (Alzheimer’s disease [AD] and healthy normal control
subjects). Each sample was incubated for 144 h after being spiked with
10 ng/ml Aβ42. To measure amyloid-β oligomers, a multimer detection
system assay was used. ***p < 0.001 versus healthy normal control
values. RLU Relative luminescence units
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interfering factors may be saturated with spiked Aβ;
hence, they may not affect to MDS signal even after 48 h
of incubation. In addition, the binding interactions be-
tween Aβ and another Aβ may be stronger than other
interfering factors for oligomerization. In previous studies,
by using protein misfolding cyclic amplification technol-
ogy, researchers were able to differentiate AβO levels by
catalyzing the misfolding and amplification of Aβ aggre-
gates by spiking Aβ42 into the CSF of patients with AD
and control individuals [44]. However, spiking Aβ into the
plasma to differentiate AβO has not previously been
published.
We observed the phenomenon that MDS signals of con-
trol subjects were still stable while we spiked the same
large amount of synthetic peptide into both AD and nor-
mal plasma samples, even after the identical incubation
step. Currently, we do not know the exact cause of the
phenomenon. Oligomerization of Aβ could be influenced
by potential factors in plasma of patients with AD but not
plasma samples from normal control. The concentrations
of these potential factors could be different in the disease
state, but they may not be present in the normal state.
We detected differential AβO dynamic changes in the
blood of patients with AD and normal control subjects,
but a direct correlation between blood and brain path-
ology remains uncharacterized. The properties of Aβ pla-
ques in the brain may differ from those in the blood
because Aβ in the blood also originates from amyloid pre-
cursor protein metabolism in skeletal muscle, organs, skin,
and peripheral cells [45, 46]. However, on the basis of pre-
vious reports, Aβ peptides cross the blood-brain barrier,
resulting in elevated Aβ levels in the CSF and plasma dur-
ing intracerebroventricular injection of synthetic Aβ42
monomers into normal imprinting control region mice
[47, 48]. It will be interesting to identify the correlation
between AβO concentrations in the plasma and amyloid
plaque deposition in the brains of patients with AD.
Conclusions
Spiked synthetic Aβ42 induced differential dynamic
changes in AβO levels in the plasma of patients with AD
compared with that of normal control subjects, as de-
tected by MDS. These observations appear to support our
hypothesis that the plasma composition and/or character-
istics of endogenous Aβ in patients with AD versus nor-
mal healthy persons are different. To our knowledge,
there have been no published reports involving the spiking
of Aβ into plasma. The characterization of differential Aβ
oligomerization dynamic changes may contribute to the
development of blood-based biomarkers for AD. However,
further studies are required to elucidate the mechanisms
underlying the formation of AβOs. Longitudinal studies
undertaken during the predementia stage of AD should
also be carried to assess clinical applications for the early
detection and monitoring of this disease.
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